Our Extended Family of Portfolio Companies

Investing in transformational ideas and entrepreneurial grit to solve major unmet needs in patient care

view more →

Developer of scientific data management software designed to enhance workplace collaboration and accelerate the rate of drug discovery. Acquired by PerkinElmer (NYS: PKI) in March 2011.

view more →

Manufacturer of late-stage clinical biopharmaceutical products. IPO in June, 2016 (NASDAQ:CLSD).

view more →

Clinipace is a clinical research organization whose services are enhanced by a proprietary on-demand software platform and clinical research services. Acquired by dMed in April 2021.

view more →

Developer of a system to enhance embolic cerebral protection. Acquired by Edwards Lifesciences (NYSE: EW) in March 2011.

view more →

Developer of biologic and medical device technologies for wound management designed to improve the safety and availability of human blood supply.

view more →

GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs.

view more →

Provider of a histotripsy platform designed for the treatment of cancer. Acquired by Bezos Expeditions, Wellington K5 Global 2025

view more →

The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor. IPO in October, 2018 (NASDAQ:PHAS)

view more →

Developer of therapies based on metalloenzyme chemistry and biology platform. Acquired by NovaQuest Capital Management in January 2018.

“It is not the critic who counts: not the man who points out how the strong man stumbles or where the doer of deeds could have done better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood, who strives valiantly, who errs and comes up short again and again, because there is no effort without error or shortcoming, but who knows the great enthusiasms, the great devotions, who spends himself in a worthy cause; who, at the best, knows, in the end, the triumph of high achievement, and who, at the worst, if he fails, at least he fails while daring greatly, so that his place shall never be with those cold and timid souls who knew neither victory nor defeat.”


Theodore Roosevelt
Speech at the Sorbonne, Paris, April 23, 1910